Ascentage Pharma

54 articles with Ascentage Pharma

• Priority Review Granted to Ascentage Pharma's New Drug Application for Olverembatinib (HQP1351), the First Third-Generation BCR-ABL Inhibitor in China

  10/21/2020

  Ascentage Pharma announced that the Center for Drug Evaluation of China's National Medical Products Administration has granted Guangzhou Healthquest Pharma Co., Ltd, a wholly-owned subsidiary of the company, priority review to its New Drug Application for Olverembatinib.

• Ascentage Pharma's Apoptosis-Targeting Drug Candidates Granted Two More Orphan Drug Designations by the US FDA

  10/9/2020

  Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted two Orphan Drug Designations (ODDs) to two of the

• Ascentage Pharma's MDM2-p53 Inhibitor APG-115 Granted Orphan Drug Designation by the FDA for the Treatment of Gastric Cancer

  9/14/2020

  Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that the US Food and Drug Administration has granted APG-115, a novel MDM2-p53 inhibitor being developed by the company, an Orphan Drug Designation for the treatment of gastric cancer.

• Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia

  9/7/2020

  Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that the US Food and Drug Administration has granted APG-2575, a novel Bcl-2 inhibitor being developed by the company, an Orphan Drug Designation for the treatment of chronic lymphocytic leukemia.

• Ascentage Pharma Releases Preclinical Results of IAP Antagonist APG-1387 in an Oral Presentation at EASL ILC 2020

  8/27/2020

  Ascentage Pharma announced that preclinical study results of the company's novel inhibitor of apoptosis proteins antagonist APG-1387 in the treatment of CHB infection have been presented in an oral presentation at the Digital International Liver Congress™ 2020 held by the European Association for the Study of the Liver.

• Ascentage Pharma Releases 2020 Interim Results, Reporting the Company's First New Drug Application and Advances in Global Strategic Collaborations

  8/18/2020

  Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its interim results for the six months ended June 30, 2020 . During the reporting period, Ascentage Pharma m

• Ascentage Pharma Becomes a Constituent of Three Major Indexes Including Hang Seng Composite Index

  8/17/2020

  Ascentage Pharma announced that the company has been selected as a constituent stock of the Hang Seng Composite Index, the Hang Seng Hong Kong-Listed Biotech Index and the Hang Seng Healthcare Index in accordance with the quarterly adjustment results of the latest index series released by Hang Seng Indexes Company Limited, with effect from September 7th, 2020.

• Ascentage Pharma Announces First Patient Dosed in the Phase Ib Study of MDM2-p53 Inhibitor APG-115 as Single Agent and in Combinations for the Treatment of Hematologic Malignancies in China

  7/22/2020

  Ascentage Pharma announced that the Phase Ib study of the company's novel MDM2-p53 inhibitor candidate APG-115 as a single agent or in combinations for the treatment of Chinese patients with relapsed/refractory acute myeloid leukemia, or relapsed/progressed high/very high risk myelodysplastic syndrome has dosed its first patient in China.

• Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Waldenström Macroglobulinemia

  7/15/2020

  Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted APG-2575, a novel Bcl-2 inhibitor being developed by

• Ascentage Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate APG-115 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors

  7/6/2020

  Ascentage Pharma announced a clinical collaboration with MSD to evaluate the combination of APG-115, Ascentage's MDM2-p53 inhibitor, and KEYTRUDA®, MSD's anti-PD-1 therapy, for the treatment of patients with advanced solid tumors.

• Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors

  6/22/2020

  Ascentage Pharma, a global, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and senescence diseases, announced a clinical collaboration with Acerta Pharma, the hematology research and development center of excellence of AstraZeneca.

• Ascentage Pharma Submits Its First New Drug Application to National Medical Products Administration, for HQP1351, the First Third-Generation BCR-ABL Inhibitor in China

  6/18/2020

  Ascentage Pharma announced that Guangzhou Healthquest Pharma Co., Ltd, a wholly-owned subsidiary of Ascentage Pharma's, has submitted a New Drug Application to the Center for Drug Evaluation of China National Medical Products Administration for HQP1351 for the treatment of patients with T315I-mutant chronic phase chronic myeloid leukemia and accelerated phase CML.

• Ascentage Pharma Announces First Patient Dosed in the Phase II Clinical Study of IAP Antagonist APG-1387 in Combination with Entecavir for the Treatment of Patients with Chronic Hepatitis B

  6/17/2020

  Ascentage Pharma announced that the Phase II clinical study of the company's novel inhibitor of apoptosis proteins antagonist APG-1387 in combination with entecavir for the treatment of patients with CHB has dosed its first patient in China.

• (ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies

  5/31/2020

  Ascentage Pharma announced that the company presented four posters of the latest clinical data on three of its drug candidates, including the MDM2-p53 inhibitor APG-115, novel Bcl-2/Bcl-xL dual inhibitor palcitoclax or APG-1252, and IAP inhibitor APG-1387, at the 2020 American Society of Clinical Oncology Annual Meeting.

• Ascentage Pharma to Present Six Abstracts at 2020 AACR Annual Meeting

  5/15/2020

  Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that the latest research progress of the company will be presented at the 2020 American Association for Cancer Research Annual Meeting.

• Ascentage Pharma to Release Clinical Advances at 2020 ASCO Annual Meeting

  5/11/2020

  Ascentage Pharma announced that latest clinical data of the company's drug candidates, including the MDM2-p53 inhibitor APG-115, novel Bcl-2/Bcl-xL dual inhibitor APG-1252, and IAP inhibitor APG-1387, will be presented in three poster discussions and a poster at the 2020 American Society of Clinical Oncology Annual Meeting.

• Ascentage Pharma's Core Drug Candidate HQP1351 Granted Fast Track Designation by the US FDA, Marking Another Milestone in Its Development

  5/7/2020

  Ascentage Pharma announced that the US Food and Drug Administration has granted HQP1351, the Company's core drug candidate, a Fast Track Designation for the treatment of patients with chronic myeloid leukemia with certain genetic mutations who have failed to respond to treatments with existing tyrosine kinase inhibitors.

• Ascentage Pharma's Core Drug Candidate HQP1351 Granted Orphan Drug Designation by the US FDA for the Treatment of Patients with Chronic Myeloid Leukemia

  5/4/2020

  Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that the US Food and Drug Administration has granted HQP1351, the Company's core drug candidate, an Orphan Drug Designation for the treatment of chronic myeloid leukemia.

• Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 for the Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in China

  4/7/2020

  Ascentage Pharma announced that it has received approval from the Center for Drug Evaluation of the China National Medical Products Administration for the Phase Ib/II study of APG-2575, the company's novel Bcl-2‒selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

• Ascentage Pharma Releases 2019 Annual Results, Reports Increased Investment in R&D and Advances in Global Clinical Development

  3/30/2020

  Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, released its annual results for the year ended December 31, 2019.